Mumps virus (MuV) is a member of the Rubulavirus genus of the family Paramyxoviridae. The virus contains a negativesense RNA genome of 15,384 nucleotides that consists of seven transcription units. The gene order is as follows: nucleoprotein (N), phosphoprotein (P), and matrix (M), fusion (F), small hydrophobic (SH), hemagglutinin-neuraminidase (HN), and large (L) proteins. Each gene encodes a single protein with the exception of the second, which encodes three proteins (V, P, and I) via RNA editing (31) . Transcription units are flanked by 3Ј and 5Ј untranslated regions (UTRs) containing consensus gene start (GS) and gene end (GE) signals and are separated by intergenic sequences of 1 to 7 nucleotides (17) . MuV virions consist of an inner helical ribonucleoprotein (RNP) core surrounded by an envelope that is derived from the host plasma membrane. The RNP is composed of the viral RNA encapsidated with N protein and associated with L and P proteins, which together form the RNA-dependent RNA polymerase. The F protein is a type I glycoprotein, synthesized as an inactive precursor (F 0 ) that is subsequently cleaved into two polypeptides (F 1 and F 2 ) which remain linked by a single disulfide bond. HN is a type II integral membrane protein.
The F and HN glycoproteins are inserted into the viral envelope and are responsible for receptor recognition and entry. The M protein is membrane associated and plays important roles in viral assembly and budding. MuV also encodes a 57-amino-acid SH integral membrane protein of unknown function. This has recently been shown to have antiapoptotic activity (48) , but like other small viral proteins, it may be multifunctional.
Recent mumps epidemics in both the United States (20) and the United Kingdom (11) demonstrate that the disease remains clinically relevant in the developed world. MuV can be successfully controlled by the use of live-attenuated virus vaccines. The Jeryl Lynn strain of MuV, originally isolated from the daughter of a prominent virologist (9) , was adapted to growth in embryonated chicken eggs and became attenuated in monkeys (18) . This strain was subsequently developed as a vaccine and was licensed in the United States in 1967. The vaccine has been shown to be a mixture of two closely related viruses, Jeryl Lynn 2 (MuV JL2 ) and Jeryl Lynn 5 (MuV JL5 ) (2) . Vaccination with a single subcutaneous dose containing 1,000 50% cell culture infective doses leads to seroconversion rates of 85% (7) . Several countries have developed alternative MuV vaccines. For example, Leningrad-3, Leningrad-Zagreb, and Urabe AM9 were developed in the Soviet Union, Croatia, and Japan, respectively (47) . Clinical studies indicated similar and in some cases higher rates of seroconversion and protective efficacy compared to Jeryl Lynn (5, 39, 44) . Unlike the Jeryl Lynn vaccine, which is not associated with aseptic meningitis (6, 39) , Leningrad-3, Leningrad-Zagreb, and Urabe AM9 have been shown to cause central nervous system (CNS) complications at unacceptably high rates in vaccinees (13, 19, 43) .
The neurotrophic nature of MuV necessitates that vaccine lots be routinely tested to ensure sufficient neuroattenuation before release. World Health Organization (WHO) guidelines require MuV vaccines to be tested in macaque monkeys (47) .
Although the monkey neurovirulence test is widely used, its reliability has been questioned, since it has been reported that this test was unable to distinguish between different vaccines and cerebrospinal fluid isolates obtained from vaccinees with aseptic meningitis (1, 36) . Thus, it has been desirable to develop alternative animal models for routine assessment of MuV neurovirulence. Attempts to develop a murine model of MuV neurovirulence have been unsuccessful, because newborn mice, infected intracerebrally with MuV KH , MuV RW , or MuV SBL-1 strains, showed no overt signs of disease, and virus was not recovered from brain samples (23) . Encephalitis in the brains of newborn hamsters infected with rodent brainadapted strains of MuV has been studied extensively (21) . Both intracerebral inoculation and intraperitoneal inoculation with the MuV KH strain lead to widespread CNS infection and mortality (21, 50) . However, the hamster model is unable to discriminate between MuV strains with known differences in human neurovirulence; comparison of the neurovirulence of three strains of MuV revealed that the nonneurovirulent Jeryl Lynn vaccine was most similar to the rodent brain-adapted MuV KH strain (51) . Intracerebral infection of neonatal Lewis rats has been demonstrated to be a particularly sensitive indicator of the relative human neurovirulence of MuV strains (34) . Intracerebral infection with 100 PFU of the MuV KH strain led to extensive hydrocephalus of the lateral and third ventricles, whereas infection with the Jeryl Lynn vaccine strain did not. Further validation of the rat neurovirulence test (RNVT) with a range of MuV strains supports the suggestion that this model can accurately discriminate MuV strains with different levels of neurovirulence (35) . In the RNVT, hydrocephalus of the lateral ventricle is measured and RNVT scores are calculated as the percentage (area) of the total brain section occupied by the lateral ventricle. RNVT scores parallel the clinical histories or attenuation status of isolates (35) . The RNVT for the prediction of MuV neurovirulence may therefore represent a significant improvement over previous animal models in terms of both accuracy and clinical relevance.
In spite of extensive efforts, an understanding of the molecular basis of MuV neurovirulence remains elusive. Sequence analysis of clinical isolates has identified positions in the HN and SH genes that may be important in neurovirulence (3, 8, 42) . In addition, neuroattenuation of clinical isolates and neuroadaptation of vaccine strains have identified mutations in the N, M, F, HN, and L genes, and these may be associated with either an increase or a decrease in neurovirulence (33) . However, no single mutation or group of mutations has been definitively identified as being associated with a neurovirulent phenotype. The development of an MuV reverse genetics system (14) and a reliable animal model for the prediction of MuV human neurovirulence (35) enables such questions to be addressed directly. In this study we utilized an MuV reverse genetics system based on the MuV JL5 vaccine strain (14) . The neurovirulence of recombinant viruses containing envelope genes from the MuV KH strain was tested using the RNVT. This approach enabled the contribution of individual genes to neurovirulence to be assessed in isolation. Evidence is presented that the F gene of MuV contains the major determinants of neurovirulence.
MATERIALS AND METHODS

Viruses and cells. The MuV
KH rodent brain-adapted strain was obtained from Steven A. Rubin (Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD). The virus had been passaged twice on Vero cells, and retention of the neurovirulent phenotype had been confirmed by intracerebral infection of Lewis rats (34) . Modified vaccinia virus Ankara (MVA-T7) was grown as previously described (15) . A549 and Vero cells were grown in Dulbecco's modified Eagle medium (Invitrogen) supplemented with 10% (vol/ vol) fetal calf serum (Invitrogen). Cells were observed by phase-contrast microscopy using a DM IRBE inverted microscope (Leica Microsystems). Photomicrographs were obtained using a DC 300F digital camera connected to a computer running IM50 imaging software (Leica Microsystems).
Multistep growth analysis. Vero cells were cultured to 70% confluence in 35-mm-diameter petri dishes. Cells were infected at a multiplicity of infection (MOI) of 0.01 for 1 h at 37°C. The inoculum was removed and replaced with Optimem (Invitrogen). Samples were taken at 12 hourly intervals up to 72 h postinfection (hpi). Cells were scraped into the supernatant, and cell-associated virus was released by freeze-thawing the samples once. Titers were determined in triplicate by the 50% end point dilution assay as previously described (15) .
Construction of an MuV expression cassette vector. The multiple cloning site (MCS) of the eukaryotic expression plasmid pCG (10) was modified to include restriction sites that are absent in the MuV JL5 full-length clone (pMuVFL). Digestion of pCG with BamHI and PstI removed the majority of the existing MCS. Two complementary oligonucleotides, priCG(MPBSH)ϩ (5Ј-GAT CCG ATA CAA CGC GTG ATA CAG TTT AAA CGA TAC ACA CGT CGA TAC AGC GAT CGC GAT ACA GTT AAC GAT ACA CTG CA-3Ј) and priCG(MPBSH)Ϫ (5Ј-GTG TAT CGT TAA CTG TAT CGC GAT CGC TGT ATC GAC GTG TGT ATC GTT TAA ACT GTA TCA CGC GTT GTA TCG-3Ј), were annealed as previously described (15) to produce an oligonucleotide linker containing MluI, PmeI, BtrI, SgfI, and HpaI restriction sites (underlined) separated by 6-bp spacers with BamHI-and PstI-compatible ends (Fig.  1A) . This was ligated into the linearized vector to generate pCG(MPBSH).
Modification of the MuV full-length cDNA clone. The full-length MuV plasmid pMuVFL was sequentially modified by site-directed mutagenesis to include a number of unique restriction sites in the UTRs flanking the M, F, SH, and HN genes. An MluI site was introduced into the P 3Ј UTR at position 3171 (numbered according to the full-length antigenomic sequence). Similarly, a PmeI site was introduced into the M 3Ј UTR at position 4465, a BtrI site was introduced into the SH 5Ј UTR at position 6248, and an SgfI site was introduced into the SH 3Ј UTR at position 6470. In addition, a BstEII site at position 6929 (located in the HN open reading frame [ORF]) was silently ablated to facilitate cloning. The resulting plasmid was designated pMuV(MPBS) (Fig. 1B) .
RNA preparation and RT-PCR. Total RNA was prepared using TRIzol solution as outlined by the manufacturer (Invitrogen). First-strand cDNA synthesis was performed on RNA (2 g) using Moloney murine leukemia virus reverse transcriptase (RT) and gene-specific primers. PCRs were set up using 2% of the cDNA reaction as a template, MuV-specific primers that flank each of the fourBtrI), SH (BtrI and SgfI), and HN (SgfI and HpaI) genes, which were generated either by RT ) were generated using similar approaches.
Sequence analysis of MuV KH envelope-associated genes. No complete genomic consensus sequence for the MuV KH strain of MuV is available. At least three independent clones were sequenced during construction of the MuV KH expression vectors using primers specific for each gene. Sequences were assembled and compared using DNA sequence analysis software (DNAStar). Clones with consensus sequences were used for all subsequent manipulations.
Construction of full-length clones with MuV KH -derived envelope-associated genes. Five plasmids that contain MuV KH envelope-associated genes were generated in pMuV(MPBS). The plasmid was cleaved with the appropriate two restriction enzymes to insert the MuV KH M (MluI and PmeI), F (PmeI and BtrI), SH (BtrI and SgfI), or HN (SgfI and NheI) gene from the pCG-based eukaryotic expression vectors. Thus, pMuV(MPBS) cleaved with MluI and PmeI and ligated with the equivalently restricted MuV KH M gene generated pMuVM KH . Constructs expressing F (pMuVF KH ), SH (pMuVSH KH ), and HN (pMuVHN KH ) were generated using similar approaches. The Kilham HN gene was inserted into SgfI-and NheI-restricted pMuVF KH to generate pMuVFHN KH , which contained both MuV KH glycoproteins. Rescue of recombinant viruses from cDNA. A549 cells, grown to 40% confluence in 35-mm-diameter petri dishes, were infected with MVA-T7 at an MOI of 0.5. Transfections were carried out essentially as outlined previously (14) . Plasmids pMuV-N (300 ng), pMuV-P (50 ng), and pMuV-L (200 ng) and the plasmids containing copies of the full-length antigenomes (6 g) were transfected into the cells over 24 h. After this time, the transfection mixtures were removed and replaced with growth medium, and the cells were incubated for a further 24 h. Vero cells (ϳ300,000) were added to each well, and monolayers were observed for as long as 10 days for the appearance of cytopathic effect. Recombinant viruses were plaque purified once in Vero cells and passaged four times to generate working stocks.
Indirect immunofluorescence and confocal scanning laser microscopy. Vero cells were grown on glass coverslips in 35-mm-diameter petri dishes to 90% confluence. Cells were infected/transfected, fixed, processed, and mounted as previously described (16) . A primary anti-MuV F monoclonal antibody (5.418) was used at a dilution of 1:500 (30 50 ) of the viruses in the right parietal area of the skull, approximately 1 mm right of the midline and midway between the eye and the ear under mild isoflurane anesthesia (10 l). Fourteen to 50 animals per virus were infected. Animals were monitored daily for signs of disease, and individuals were sacrificed by isoflurane narcosis between 3 and 30 days postinfection (dpi). All experimentation was carried out under appropriate animal licenses regulated by the Home Office. Whole brains were removed and immersed in 10% (vol/vol) buffered formalin. Brains were blocked into right and left hemispheres, processed, and embedded in paraffin wax. Whole brains from animals at 3 dpi were homogenized in Optimem (3 ml), and virus was recovered following a single freeze-thawing. Homogenized samples were centrifuged at 4,000 ϫ g for 5 min. Clarified supernatant was added to Vero cells grown to a confluence of 70% in 35-mm-diameter petri dishes. Total RNA was prepared from the cell pellet using TRIzol solution. RT-PCRs were set up using total RNA (1 g), MuV-specific primers priMuV JL5 3993ϩ (5Ј-GGT TCC ACC TAT GTA ATC TG-3Ј) and priMuV JL5 4681Ϫ (5Ј-CTT GAC TAC TAC GTA GGA GC-3Ј), and a Reverse-iT one-step kit (ABgene).
Pathological and immunohistochemical assessment. Microtome-cut sections (thickness, 7 m) were taken at a distance of 200 m from the midline of the paraffin-embedded tissue (16) . Sections were dewaxed, and after microwave antigen retrieval, a monoclonal antibody that recognizes the N protein of MuV (N93-51/01) was used for immunohistochemistry at a dilution of 1:4,000. Specific binding sites were immunodetected as previously described (38) .
Hematoxylin and eosin-stained brain sections were digitized using a ScanScope slide scanner (Aperio Technologies) and viewed using an Imagescope (version 5.00) virtual slide viewing software package (Aperio Technologies). Sections were viewed at equivalent magnifications, and a snapshot was exported as a tagged image format file. These were further analyzed using ImageJ 1.33u image processing and analysis software (National Institutes of Health). Regions of interest (ROI) were selected using a polygon selection tool. The entire brain section, excluding the cerebellum and olfactory bulb, was selected (ROI 1), and the area was determined in pixels. The lateral ventricle was selected (ROI 2), and the area was determined in pixels. The extent of hydrocephalus (RNVT score) was expressed as the percentage of the total brain section occupied by the lateral ventricle, i.e., (ROI 2/ROI 1) ϫ 100.
Nucleotide sequence accession numbers. Sequences of MuV KH envelopeassociated genes have been submitted to GenBank under accession numbers EF493023 (M), EF493024 (F), EF493025 (SH), and EF493026 (HN).
RESULTS
Generation of constructs expressing MuV envelope-associated genes. The goal of this study was to determine if the envelope-associated proteins of the MuV KH strain were capable of conferring a neurovirulent phenotype on a nonneurovirulent vaccine strain and, if so, which genes were required. Sequences of the UTRs flanking each of the genes were examined for areas that could be altered to restriction sites absent in the MuV JL5 full-length clone. Regions outside the consensus GS and GE signals were chosen, and four sites (MluI, PmeI, BtrI, and SgfI) that flanked M, F, and SH were introduced (Fig. 1B) . These sites introduce either 2 or 3 nucleotide changes into the UTRs, resulting in a total of 12 nucleotide changes from the MuV JL5 consensus. Endogenous restriction sites (NheI and HpaI) at the 3Ј end of the HN ORF and the 5Ј end of the L ORF were used in combination with the SgfI site to facilitate the cloning of HN ORFs. The MCS of a eukaryotic expression plasmid was modified to include these sites using synthetic oligonucleotides (Fig. 1A) N 34 H (41) . Surprisingly, 11 amino acid residues differed between our HN and the previously published sequence. At five of these positions (176, 385, 389, 447, and 523) our sequence predicted the highly (Ͼ95%) or totally conserved amino acid in an alignment of all 69 complete HN sequences available on GenBank. At three positions (372, 473, and 474), two amino acids were given in the alignment, with our sequence predicting one and the previously published sequence predicting the other amino acid. Positions 354 and 356 are variable in the alignment, whereas at position 297 we predicted a phenylalanine instead of the conserved leucine found in other sequences. Amino acid differences between our MuV KH and MuV JL5 are summarized in N2K  V14L  I44T  I207V  Y11F  Y34H  S69F  M274I  T24I  A37T  I135V  R373S  L95P  H55Q  A218V  S177N  I279T  Y290H  T288K  M331I  L297F  T431A  L336S  F477V  Q354S  G480S  Y442S  S489A  H464N  I473T were transfected into Vero cells to determine if homologous and heterologous pairs of MuV glycoproteins could cooperate to give fusion. Neither F nor HN formed syncytia in isolation (data not shown), and transfection with homologous plasmids resulted in the formation of syncytia 24 h posttransfection (hpt) ( Fig. 2A and B) . Cell fusion was quantified by counting the number of nuclei contained within syncytia in 20 randomly chosen fields of view. Coexpression of MuV JL5 F and HN produced higher levels of fusion than coexpression of MuV KH F and HN (Fig. 2E) . Transient transfection of heterologous sets of glycoprotein expression vectors from each strain indicated that the glycoproteins complemented one another and formed functional fusion complexes (Fig. 2C and D) . Surprisingly, expression of MuV JL5 F with MuV KH HN resulted in a significant increase in the level of cell fusion, and the monolayer was extensively fused within 48 h (Fig. 2C) . In contrast, expression of MuV KH F with MuV JL5 HN resulted in very limited cell fusion (Fig. 2D) . Quantification of cell fusion confirmed that expression of MuV JL5 F with MuV KH HN produced higher levels of fusion than either of the homologous glycoprotein combinations, whereas expression of MuV KH F with MuV JL5 HN produced lower levels than either of the homologous glycoprotein combinations (Fig. 2E) . Taken together, these data indicated that the glycoproteins from both MuV JL5 and MuV KH could form functional fusion complexes even when heterologous combinations were expressed and suggested that recombinant viruses containing such combinations may be viable.
Generation of recombinant viruses expressing the envelopeassociated genes from MuV
KH . A series of full-length plasmids that contained individual MuV KH envelope-associated genes were constructed (Fig. 1C) . In addition, a clone (pMuVFHN KH ) containing both viral glycoproteins was constructed. A rescue system based on pMuV(MPBS) was employed to generate recombinant viruses from each construct. The recombinant viruses were used to infect Vero cells at an MOI of 0.01, and the level of cell-to-cell fusion was recorded after 24 and 48 h. All viruses induced syncytia in Vero cells to a lesser or greater extent (Fig. 3) (1 g) (D). Phase-contrast images were taken 24 and 48 hpt. Equivalent transfections were performed on Vero cells grown on glass coverslips. At 24 and 48 hpt, cells were fixed and immunocytochemistry was performed using a primary anti-MuV F monoclonal antibody (5.418) at a dilution of 1:500 and a fluorescein isothiocyanate-conjugated secondary antibody at a dilution of 1:100. Nuclei were counterstained using propidium iodide. (E) Fusion was quantified by counting the number of cell nuclei involved in syncytia in 20 randomly chosen fields of view.
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MUMPS VIRUS NEUROVIRULENCE 8297 TCID 50 /ml at 60 hpi (Fig. 4) . The MuV KH strain and the recombinant virus rMuVF KH grew to higher titers of approximately 10 7 at 60 hpi. The recombinant virus rMuVM KH achieved a titer of approximately 10 6.5 TCID 50 /ml at 60 hpi. These data indicated that the introduction of nonhomologous genes into rMuV MPBS had no adverse effect on the growth of the recombinant viruses.
The F gene of MuV KH is a major determinant of neurovirulence. The severity of hydrocephalus following intracerebral inoculation of neonatal Lewis rats with MuV has been shown previously to correlate with the known human neurovirulence of various MuV isolates (35) . This model was utilized to assess the neurovirulence phenotypes of each of the recombinant viruses. One-day-old Lewis rats (n, 14 to 50) were inoculated intracerebrally with 100 TCID 50 of each virus. At 30 dpi, rats were euthanized and the severity of hydrocephalus (RNVT score) was determined as the percentage of the brain crosssection occupied by the lateral ventricle. Representative crosssections for each virus infection are shown in Fig. 5A . Few animals infected with the parental rMuV MPBS virus developed hydrocephalus, whereas extensive dilation of the lateral ventricle was observed in many animals infected with MuV KH (Fig. 5B) . Not all animals infected with MuV KH developed hydrocephalus. However, all data points were included in the analysis. The average severity of hydrocephalus was determined as 0.8% Ϯ 0.3% for rMuV MPBS versus 12.7% Ϯ 1.3% for MuV KH . Recombinant viruses based on rMuV MPBS containing genes from MuV KH were also examined. Viruses containing the MuV KH M, SH, or HN gene in isolation failed to induce significant hydrocephalus, whereas a virus that contained the MuV KH F gene induced severe hydrocephalus in many animals (8.4% Ϯ 1.1%). A virus containing both the MuV KH glycoproteins induced a marginally higher level of hydrocephalus (10.5% Ϯ 2.1%), although this was not statistically different from the level for the MuV KH F-containing virus in an unpaired Student t test (P ϭ 0.36).
Infection of neonatal Lewis rats was confirmed by both RT-PCR and isolation of virus from the brain tissue of a single animal from each virus group at 3 dpi (data not shown). Viral titers were highest for those viruses which induced hydrocephalus, with rMuVF KH , rMuVFHN KH , and MuV KH reaching titers of 10 2.2 , 10 4.5 , and 10 6.0 TCID 50 /g of brain tissue, respectively. Detection of MuV N antigen in brain sections of animals at 3 dpi was also performed for a limited number of animals infected with rMuV MPBS , rMuVF KH , rMuVHN KH , and rMuVFHN KH , since these viruses induced hydrocephalus to a lesser or greater extent (Fig. 6) . Antigen-positive cells were detected for each virus examined. Infection was restricted to the ependymal cells, which line the ventricular system. animals infected with those viruses that did not induce hydrocephalus (i.e., rMuV MPBS and rMuVHN KH ) compared to those viruses that did induce hydrocephalus (i.e., rMuVF KH and rMuVFHN KH ).
DISCUSSION
The identification of molecular markers of MuV neurovirulence has been hampered in large part by the lack of a suitable small-animal model capable of reliably predicting the potential neurovirulence of virus strains. The development of the RNVT represents a significant improvement over previous models and, in combination with the MuV rescue system, has enabled the current study to be carried out.
Recently another group published a sequence for the MuV KH HN gene (32) . Comparison of this sequence with that derived in this study revealed a total of 11 amino acid differences. The HN sequence determined here was derived directly from a stock of MuV KH that was shown to be neurovirulent in rats. The phenotype of the MuV KH strain used in the other study was not investigated, and thus whether the differences would render it nonpathogenic is unknown. The protein of the strain used in this study was able to induce syncytia in transiently transfected cells when coexpressed with both homologous and heterologous F proteins. A recombinant virus that expressed only MuV KH HN was viable and grew to titers of approximately 10 5.5 TCID 50 /ml. Furthermore, a recombinant virus that expressed both HN and F from our MuV KH was able to induce hydrocephalus in rat brains to a similar degree as MuV KH . However, in light of these sequence differences, further work will be needed in order to clarify the contribution of MuV KH HN to neurovirulence. To date, most studies of the role of specific mutations in MuV neurovirulence have concentrated on the HN protein. Growth of MuV KH in the presence of a monoclonal antibody known to inhibit the hemagglutination of human erythrocytes resulted in the isolation of several mutants with increased neuraminidase activity (24) . One of the mutants (M13) was found to have reduced neurovirulence in hamsters following intracerebral inoculation compared to the parental MuV KH strain. Analysis of infected brains by immunohistochemistry revealed that MuV KH -infected animals had widespread infection of the CNS involving both ependymal cells and neurons. In contrast, the viral antigen in M13-inoculated animals was largely restricted to ependymal cells, with only isolated neurons infected. In a subsequent study, the HN genes, but not the other envelope components, of the antibody escape mutants were sequenced (22) . Mutant M13 was found to contain a single nonconservative mutation (HN 360 R3C), indicating that HN plays an important role in neurovirulence. Sequence analysis of the Urabe AM9 component of the Trivirix measles, mumps, and rubella vaccine produced by Smith, Kline & French with cerebrospinal fluid isolates from postvaccination meningitis cases revealed that the vaccine is actually a mixture of at least two strains of virus that differ at amino acid 335 (8) . Postvaccination meningitis appears to result from selection of the HN K335 variants. However, a subsequent study was unable to find a correlation of HN K335 with postvaccination complications (4). The Jeryl Lynn vaccine, which is not associated with high rates of postvaccination meningitis, also contains K335 in the HN proteins of both the MuV JL2 and MuV JL5 components, indicating that this single amino acid is not sufficient to confer a neurovirulent phenotype (28) . These inconsistencies in the suggested link of genotype and phenotype suggest that there are other mutations elsewhere in the genome that play a key role in neurovirulence.
In contrast to earlier studies, the ability to generate recombinant MuV that can be assessed in a reliable animal model has enabled the contribution of individual genes to neurovirulence to be investigated. (33) . The neuroattenuated 88-1961 variant (88-1961-CEF) contained single-amino-acid substitutions in the F, HN, and L proteins. Amino acid 91 of the F protein, which is a heterogeneous mixture of proline and threonine in the parental stock, became homogeneous for threonine, which is part of a potential Nlinked glycosylation site. Later studies by the same group support the suggestion that neurovirulence is associated with changes in the level of genetic heterogeneity at specific sites (37) . Neuroattenuation of the Urabe AM9 strain on CEF and Vero cells was accompanied by changes in heterogeneity at several positions. The F gene contained four positions that either lost or gained heterogeneity (amino acids 120, 290, 370, and 393). It is noteworthy that position 290 is one of the nine positions where the F genes of MuV KH and MuV JL5 differ. For paramyxoviruses such as Newcastle disease virus, the capacity of the host cell to proteolytically cleave the F 0 protein correlates directly with virulence (29) . However, the inability of some MuV strains to induce cell-to-cell fusion is not a result of uncleaved precursor F protein (26) . The neuraminidase activity of the HN protein is an important factor in MuV cell-to-cell fusion (27) . Strains with high neuraminidase activity, as determined by the hydrolysis of fetuin, cause no cell fusion, whereas strains with low neuraminidase activity cause extensive fusion. This observation is thought to be a consequence of the prolonged association of progeny virus with the plasma membrane of adjacent cells, resulting in increased cellto-cell fusion. Strains with high neuraminidase activity are associated with the plasma membrane for a much shorter duration and so are less likely to induce cell-to-cell fusion. Studies on influenza virus have demonstrated that strains with low neuraminidase activity are more fusogenic (12) and are more pathogenic in mice (25) . For MuV, the relationship between FIG. 5 . Assessment of neurovirulence of the recombinant viruses in rats. One-day-old Lewis rats were inoculated intracerebrally with 100 TCID 50 of rMuV MPBS (n ϭ 21), rMuVM KH (n ϭ 24), rMuVF KH (n ϭ 50), rMuVSH KH (n ϭ 19), rMuVHN KH (n ϭ 24), rMuVFHN KH (n ϭ 14), or MuV KH (n ϭ 22). Animals were sacrificed 30 dpi, and whole brains were removed, blocked into right and left hemispheres, processed, and embedded in paraffin wax. Microtome-cut sections (7 m) were taken at a distance of 200 m from the midline of the paraffinembedded tissue and stained with hematoxylin and eosin. (A) Representative sections from animals infected with each of the recombinant viruses. (B) Sections were digitized, and the extent of hydrocephalus (RNVT score) was expressed as the percentage of the total brain section occupied by the lateral ventricle. fusion in vitro and virulence in both humans and animal models is less well understood. In one study, the nonfusing RW strain of MuV was grown in the presence of the competitive inhibitor of sialidase, 2-deoxy-2,3-dehydro-N-acetylneuraminic acid (DANA), and a sialidase-deficient variant that caused extensive syncytium formation in cell culture was obtained (45) . Sequence data revealed two mutations in the fusing variant, HN 181 I3T and HN 261 G3K. However, intracerebral inoculation of neonatal hamsters with this variant produced an infection that the author described as indistinguishable from the nonfusing parental form (49) . This suggests that there is no direct association between increased fusogenicity and neurovirulence. Moreover, in the current study, recombinant viruses that were more fusogenic, such as rMuV MPBS differ at a limited number of positions, the generation of recombinant viruses containing individual mutations in isolation will allow the contribution of each of these to neurovirulence to be assessed. It will also be of interest to determine if the N, P, and L genes of MuV KH contain determinants of neurovirulence by generating recombinant viruses expressing these in isolation or as a complex. Furthermore, the generation of recombinant viruses expressing genes from viruses known to be neurovirulent in humans, such as Urabe AM9, will be necessary to confirm that the MuV F gene is a major determinant of human neurovirulence.
